| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018571095 |
| P356 | DOI | 10.1038/SJ.BJC.6605375 |
| P932 | PMC publication ID | 2778545 |
| P698 | PubMed publication ID | 19844235 |
| P5875 | ResearchGate publication ID | 38025198 |
| P2093 | author name string | K Shimada | |
| K Hotta | |||
| Y Nakajima | |||
| H Kanehiro | |||
| H Yagita | |||
| N Konishi | |||
| T Akahori | |||
| I Yamato | |||
| M Sho | |||
| T Nomi | |||
| P2860 | cites work | B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production | Q24290870 |
| Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses | Q24316331 | ||
| Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis | Q24562910 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer | Q28245751 | ||
| Characterization of mouse and human B7-H3 genes | Q28513270 | ||
| The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses | Q28594992 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Pancreatic cancer | Q29622871 | ||
| Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 | ||
| Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis | Q33788244 | ||
| Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. | Q34294986 | ||
| B7-H3 promotes acute and chronic allograft rejection | Q34389662 | ||
| Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial | Q34602771 | ||
| Immunotherapy for pancreatic cancer - science driving clinical progress | Q36133140 | ||
| Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade | Q36286133 | ||
| B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome | Q36288654 | ||
| Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients | Q36498459 | ||
| Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer | Q36539266 | ||
| Current immunotherapeutic strategies in pancreatic cancer | Q37005912 | ||
| Fine tuning the immune response through B7-H3 and B7-H4 | Q37227080 | ||
| B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. | Q39943889 | ||
| B7-H3 and B7-H4 expression in non-small-cell lung cancer | Q40266187 | ||
| An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. | Q40277507 | ||
| Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 | ||
| Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells | Q40395815 | ||
| B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells | Q40501998 | ||
| Pancreatic cancer: surgery alone is not sufficient | Q44918342 | ||
| Mouse B7-H3 induces antitumor immunity. | Q45864958 | ||
| Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas | Q46746290 | ||
| Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size | Q47177328 | ||
| Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. | Q53536649 | ||
| Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. | Q54287306 | ||
| Murine B7-H3 is a negative regulator of T cells | Q80418692 | ||
| B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy | Q80767732 | ||
| Immunotherapy and chemotherapy--a practical partnership | Q81703535 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 1709-1716 | |
| P577 | publication date | 2009-10-20 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Clinical importance of B7-H3 expression in human pancreatic cancer | |
| P478 | volume | 101 |
| Q50138482 | 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models |
| Q38036543 | A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. |
| Q38966400 | Aberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis |
| Q50983217 | B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. |
| Q33967711 | B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients |
| Q36640287 | B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer |
| Q37301864 | B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy |
| Q47138333 | B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells |
| Q39524901 | B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes |
| Q34446315 | B7-H3 expression in breast cancer and upregulation of VEGF through gene silence |
| Q34105913 | B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome |
| Q47233613 | B7-H3 in tumors: friend or foe for tumor immunity? |
| Q39325949 | B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence |
| Q34935785 | B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis |
| Q33703916 | B7-H3 overexpression in pancreatic cancer promotes tumor progression |
| Q35867721 | B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells |
| Q35660790 | B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation |
| Q89457607 | B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models |
| Q36429035 | B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma |
| Q38135281 | B7-H3-mediated tumor immunology: Friend or foe? |
| Q34356712 | B7-h3 and its role in antitumor immunity |
| Q57176931 | B7H3 As a Promoter of Metastasis and Promising Therapeutic Target |
| Q104693710 | Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate |
| Q35032331 | Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma |
| Q37269305 | Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer |
| Q37116249 | Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer |
| Q42728633 | Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. |
| Q35871253 | Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma |
| Q34538321 | Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients |
| Q26765123 | From bench to bedside a comprehensive review of pancreatic cancer immunotherapy |
| Q60923369 | Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3 |
| Q47426456 | Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo |
| Q36207260 | Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response |
| Q54973593 | High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder. |
| Q36444198 | Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. |
| Q35104159 | Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c |
| Q39446788 | Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone |
| Q64973209 | Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q39274136 | Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response |
| Q38040302 | MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. |
| Q26999345 | Molecular mechanism underlying lymphatic metastasis in pancreatic cancer |
| Q37697212 | Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer |
| Q93054462 | Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas |
| Q28075712 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations |
| Q35886496 | Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy |
| Q35870682 | Pancreatic ductal adenocarcinoma: a review of immunologic aspects |
| Q50959680 | Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. |
| Q47150218 | Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis |
| Q36621122 | Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma |
| Q97537680 | Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling |
| Q39163764 | Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo |
| Q38445328 | Strategies to relieve immunosuppression in pancreatic cancer. |
| Q37721055 | Structure and T cell inhibition properties of B7 family member, B7-H3. |
| Q34577158 | T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics |
| Q37362510 | The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer |
| Q34093668 | The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer |
| Q38684886 | The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. |
| Q92618860 | The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer |
| Q39160982 | The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. |
| Q89571179 | Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer |
| Q48673154 | WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. |
Search more.